CIPN manifests as a constellation of sensory and motor impairments, including numbness, burning sensations, tingling, and muscle weakness that predominantly affect the feet. These symptoms often develop insidiously during or after chemotherapy, dramatically reducing patient quality of life. The underlying pathophysiology involves the neurotoxic effects of chemotherapy agents that damage peripheral nerves, especially in distal limbs where nerves are longest and most vulnerable. This damage disrupts normal nerve signaling, leading to the characteristic “pins and needles” feeling and loss of proprioception. Importantly, these neurological deficits can persist indefinitely, highlighting the critical need for early detection and management.

The University of South Australia conducted a comprehensive analysis of 3,292 colorectal cancer patients, among whom 82% received Oxaliplatin-based chemotherapy. Colorectal cancer represents a significant cohort given the widespread use of neurotoxic chemotherapy in its management. Despite the well-documented risk of CIPN associated with Oxaliplatin, the study revealed a startling statistic: only a minority of these patients engaged podiatry services within five years post-treatment. This lack of engagement suggests a profound disconnect between the recognition of CIPN symptoms and the integration of foot care into cancer survivorship plans.

Podiatrists possess specialized skills in managing lower limb disorders and are uniquely positioned to address the multifaceted challenges posed by CIPN. Their expertise encompasses assessment, prevention, and treatment strategies aimed at preserving neuromuscular function, preventing falls, and minimizing foot trauma. Early podiatric intervention can contribute to fall prevention—a critical factor given that CIPN-related balance impairments significantly heighten fall risk. Moreover, effective podiatric care can reduce the incidence of ulcerations and infections, which, if left untreated, may escalate to amputations. These complications underscore the potential life-altering consequences of neglecting foot health in chemotherapy patients.

Current oncology protocols often overlook podiatric involvement, focusing primarily on cancer control while underappreciating long-term functional impairments. This study highlights the urgent necessity for oncology care teams to integrate routine podiatric evaluations into survivorship programs. By routinely screening for CIPN symptoms and referring patients early to podiatrists, clinicians could enhance patient outcomes, reduce morbidity, and improve adherence to chemotherapy regimens by mitigating symptom severity. Indeed, severe CIPN symptoms sometimes prompt patients to discontinue treatment prematurely, adversely impacting cancer prognosis.

The absence of national guidelines specific to CIPN prevention and management in Australia exacerbates the challenge of coordinated care. Presently, the solitary published clinical pathway for CIPN management does not incorporate podiatry services, signifying a critical oversight in multidisciplinary care frameworks. To bridge this gap, the UniSA research team, with consensus from Australian podiatry professionals, has developed clinical recommendations emphasizing podiatry’s essential role. These guidelines advocate for early assessment and ongoing management to combat CIPN symptoms proactively, though awareness and implementation of these protocols remain limited.

Understanding the neurobiological mechanisms behind CIPN is pivotal in developing effective care strategies. Neurotoxicity induced by chemotherapy agents leads to axonal degeneration and mitochondrial dysfunction in sensory neurons, impairing nerve conduction velocity and causing debilitating sensory deficits. The resultant proprioceptive loss impairs patients’ ability to maintain balance, increasing susceptibility to falls and subsequent injuries. Podiatric interventions aimed at strengthening foot musculature, improving proprioceptive feedback, and providing protective orthotics can counterbalance these deficits, thereby safeguarding patient mobility and independence.

The study emphasizes that podiatry’s role transcends symptom relief, encompassing vital preventative care that reduces downstream complications. Considering that novel pharmacological agents to prevent or reverse CIPN are currently unavailable, supportive care through podiatry becomes indispensable. Preventing ulcerations and infections in the neuropathic foot can significantly diminish hospitalizations and improve survivorship quality, especially among aging cancer populations with comorbidities such as diabetes.

Education forms another cornerstone for addressing this silent crisis. Both patients and oncology clinicians often harbor limited knowledge regarding the benefits of podiatric care in CIPN management. Enhancing awareness through targeted education campaigns could promote earlier referrals and empower patients to seek necessary interventions. Early identification and treatment may also alleviate psychological distress linked to persistent pain and functional impairments, fostering better overall wellbeing.

The UniSA research elucidates a pressing need for systemic change in cancer care models. Embedding podiatry within multidisciplinary oncology teams, alongside oncologists, nurses, and physiotherapists, could holistically address the complex challenges posed by CIPN. Such collaboration would facilitate integrated pathways where referrals are streamlined, and patients receive timely, personalized care to manage neuropathic symptoms effectively.

In conclusion, Chemotherapy-Induced Peripheral Neuropathy remains a significant yet underrecognized adverse effect of cancer treatment, profoundly impacting lower limb function and patient quality of life. The University of South Australia’s study casts a spotlight on an alarming service gap where many patients miss critical podiatric support that could mitigate CIPN’s damaging effects. Addressing this involves not only clinical guideline revisions and health system reforms but also an urgent cultural shift within oncology care paradigms. By repositioning podiatry at the forefront of CIPN management, healthcare providers can enhance survivorship outcomes and ensure that cancer treatment’s triumph is not overshadowed by preventable complications.

Subject of Research: Not applicable

Article Title: Patterns and Factors Associated with Podiatry Service Use Among Colorectal Cancer Patients Following Chemotherapy in South Australia: Focus on Chemotherapy-Induced Peripheral Neuropathy (CIPN)

News Publication Date: 3-Oct-2025

Web References: http://dx.doi.org/10.2147/JMDH.S552589

References: The authors declare there are no competing or conflicts of interest in this work.

Keywords: Cancer treatments, Chemotherapy, Side effects, Medical treatments

The theme for this year’s ASCO assembly, “Driving Knowledge to Action. Building a Better Future,” underscores the critical nexus between cutting-edge research and patient-centered clinical application. City of Hope’s delegation is poised to contribute robust data sets and innovative research paradigms that spotlight precision oncology, novel therapeutic agents, and advanced management approaches for various malignancies including breast, pancreatic, colorectal, prostate, kidney, and hematologic cancers. Moreover, the emphasis on integrative and supportive care, such as palliative interventions, marks a progressive step towards holistic cancer treatment pathways that prioritize quality of life alongside survival metrics.

Central to City of Hope’s presentations are several key oral abstract and clinical symposium sessions that dissect tumor biology and therapeutic resistance in high-risk renal cell carcinoma. The IMmotion010 study, a randomized phase 3 trial exploring adjuvant atezolizumab versus placebo, will unveil comprehensive genomic characterizations of baseline and post-progression tumors. This analysis promises to elucidate mechanisms of immune evasion and tumor evolution, potentially guiding biomarker-driven treatment algorithms in kidney cancer. Leading this discourse is Dr. Sumanta Kumar Pal, a seasoned medical oncologist with extensive expertise in therapeutic research at City of Hope.

Complementing the genomic insights, City of Hope also emphasizes symptom science and palliative care, acknowledging the indispensable role these disciplines play in oncology. Dr. Tanyanika Phillips will chair a session focusing on the management of cancer-related symptoms and the integration of palliative care principles within standard oncology practice. This aligns with the growing recognition that addressing treatment side effects and symptom burden is fundamental to enhancing patient outcomes and curbing healthcare costs.

Dr. Heather Hampel’s involvement as chair and panelist in a session dedicated to hereditary cancer demonstrates City of Hope’s commitment to genetic risk stratification and precision prevention. By delving deeper into hereditary cancer risk and its clinical repercussions, the session will underscore advances in genetic counseling and germline testing that can personalize cancer surveillance and prophylactic strategies.

Rapid oral abstract sessions will highlight groundbreaking work in breast cancer therapy and hematologic malignancies. The investigation led by Dr. Hope S. Rugo into treatment rechallenge following trastuzumab-deruxtecan-related interstitial lung disease addresses a critical safety and efficacy question in metastatic breast cancer management. Understanding how to safely reintroduce this potent antibody-drug conjugate after pulmonary toxicity could expand therapeutic options for patients with resistant disease.

In leukemia research, Dr. Ibrahim T. Aldoss presents a post hoc analysis from the Phase 3 PhALLCON trial regarding minimal residual disease (MRD) negativity after induction therapy. MRD status serves as a highly sensitive biomarker predictive of relapse and survival, and optimizing treatment to achieve MRD negativity is a paramount goal in acute leukemia management. These findings can expedite the adoption of MRD-guided therapeutic decision-making.

Innovations in myeloma treatment will be critically discussed through City of Hope’s participation as a discussant in sessions exploring novel therapeutic avenues targeting plasma cell dyscrasias. Dr. Amrita Krishnan’s expertise enhances the dialogue surrounding emerging regimens and biomarker-driven interventions aimed at improving long-term disease control and patient quality of life in multiple myeloma.

Educational sessions curated by City of Hope further underscore emerging challenges in oncology. Dr. Hope S. Rugo’s presentation on managing endocrine toxicities serves to equip oncologists with best practices for mitigating adverse effects related to novel breast cancer therapies. This is pivotal as new agents with complex side effect profiles enter clinical use, requiring nuanced management strategies to maintain treatment adherence.

Pediatric oncology survivors’ morbidity reduction is addressed in a session led by Dr. Saro H. Armenian, who advocates for personalized intervention approaches. This focus highlights survivorship care as a critical extension of cancer therapy, addressing long-term consequences of childhood cancer treatment through tailored risk assessment and supportive care techniques.

Integrative oncology is also represented, with Dr. Krisstina Gowin presenting evidence-based guidelines for the management of cancer-associated pain, fatigue, and depression. By operationalizing ASCO’s supportive care guidelines into real-world practice, these sessions promote holistic, patient-centered care models that integrate conventional and complementary modalities.

Poster presentations extend the scope of City of Hope’s research portfolio, showcasing innovative clinical trial data across metastatic breast cancer, pancreatic ductal adenocarcinoma, colorectal cancer, and genitourinary malignancies. Notably, the NAPOLI 3 Phase 3 trial final overall survival analysis in metastatic pancreatic cancer, presented by Dr. Vincent Chung, offers fresh perspectives on treatment efficacy and long-term survival characteristics. Similarly, evaluations of novel immunotherapies and combinatorial regimens in kidney and prostate cancers provide important insights into optimizing sequencing and combination strategies.

Recognition of City of Hope faculty members such as Drs. Lorna Rodriguez-Rodriguez and Stacy W. Gray, who were inducted as fellows of the American Society of Clinical Oncology (FASCO), reflects the institution’s dedication to leadership in oncology research, education, and clinical excellence. This honor acknowledges their pivotal roles in fostering innovation and advancing standards of care to conquer cancer effectively.

City of Hope’s integrated research-to-practice model, underscored by its NCI-designated comprehensive cancer center, continues to influence oncology globally. The institution’s contributions at the 2025 ASCO Annual Meeting epitomize a mission-driven commitment to transforming complex cancer data into actionable clinical applications that improve patient survival and wellbeing. By converging basic science, translational research, and clinical expertise, City of Hope underscores the future of oncology—a future where knowledge unequivocally drives transformative cancer care.

As oncology confronts the challenges of heterogeneity, resistance mechanisms, and survivorship complexities, City of Hope’s broad research landscape—from molecular tumor characterization to supportive care innovation—foreshadows a new horizon in personalized and effective cancer management worldwide.

Subject of Research: Oncology research and clinical advancements across multiple cancer types, including renal cell carcinoma, breast cancer, pancreatic cancer, colorectal cancer, prostate cancer, kidney cancer, blood cancers, and supportive care modalities.

Article Title: City of Hope Unveils Pioneering Oncology Research at 2025 ASCO Annual Meeting

News Publication Date: Not specified in the provided content

Web References:

• https://meetings.asco.org/2025-asco-annual-meeting
• https://www.cityofhope.org/

References: Not explicitly provided in the content

Image Credits: Not provided

Keywords: Oncology, Cancer Research, Precision Medicine, Immunotherapy, Hematologic Malignancies, Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Clinical Trials, Supportive Care, Palliative Care

Financial toxicity, a term increasingly recognized in oncological discourse, describes the economic hardship cancer patients face due to direct medical costs, indirect expenses, and income loss. This burden is especially pronounced in lung cancer patients, where treatment regimens are often prolonged, complex, and expensive. The recent study conducted in Shandong Province, China, provides a comprehensive analysis of how FT manifests and varies among different patient profiles, emphasizing that this issue is far from uniform and demands personalized intervention strategies.

The research team employed a cross-sectional design involving 421 lung cancer patients recruited from two high-level hospitals. Utilizing validated instruments—including a financial toxicity scale tailored for cancer populations, alongside quality of life, social support, and mental resilience assessments—the study delineated the financial distress spectrum with a sophisticated methodological approach. Crucially, the investigators applied latent profile analysis, an advanced statistical technique, to classify patients into discreet FT categories based on their symptom severity and socio-demographic variables.

Analysis revealed a striking heterogeneity within the cohort: approximately 19.5% experienced mild financial toxicity, while 7.8% fell into a ‘moderate resource-deficient’ group characterized by limited financial resources and support. Notably, a substantial subset (35.6%) exhibited a ‘moderate balanced’ profile, reflecting moderate toxicity balanced by some coping resources. Alarming was the 37.1% labeled as ‘severe’ FT, underscoring a vast portion of lung cancer patients enduring debilitating economic pressure.

Multivariate logistic regression further illuminated pivotal factors influencing FT severity. Frequent hospitalizations emerged as a significant predictor, likely increasing both direct treatment costs and indirect expenditures such as transportation and lost wages. Lifestyle modifications, often necessary to accommodate treatment side effects or financial constraints, also correlated with more severe FT. Employment status played a crucial role; unemployed or underemployed patients were disproportionately burdened, revealing the economic vulnerability accompanying cancer diagnoses.

Insurance coverage, a common mitigating factor in healthcare economics, showed a complex relationship with FT levels. Patients lacking comprehensive insurance were predictably more susceptible to financial hardship, yet the nuances of coverage adequacy and reimbursement policies influenced outcomes beyond mere enrollment. Educational attainment surfaced as another determinant, potentially reflecting differences in health literacy and resource navigation abilities critical for accessing financial support programs.

Intriguingly, psychosocial variables such as social support and emotional distress were tightly linked to financial toxicity. Patients with robust social networks generally experienced lower financial strain, suggesting emotional and practical support mechanisms buffer economic stress. Conversely, heightened emotional distress correlated with severe FT, pointing to a bidirectional relationship where economic hardship exacerbates psychological suffering, which in turn may impair financial management capabilities.

Family resilience and problem-solving capacity appeared as protective factors within the analysis. Families capable of adaptive coping and collaborative decision-making helped moderate the financial strain imposed by lung cancer treatments, highlighting the importance of involving caregivers in holistic financial counseling. Furthermore, the ability to mobilize social resources—be it community programs, charitable aid, or governmental assistance—also dictated patients’ financial trajectories.

The implications of this research extend beyond epidemiological profiling. Given that over 70% of patients experienced moderate to severe financial toxicity, clinical interventions must evolve to incorporate economic screening as a routine component of patient assessment. Early identification of high-risk groups enables targeted deployment of multi-dimensional support including psychological counseling, financial navigation, cost-containment strategies, and health literacy enhancement.

Financial navigation programs, in particular, show promise by guiding patients through complex insurance landscapes, identifying eligibility for assistance programs, and optimizing treatment affordability without compromising care quality. Psychological interventions aimed at reducing emotional distress and enhancing resilience may alleviate the compounding effects of mental health on economic outcomes, establishing a holistic model for managing FT.

Moreover, health literacy emerges as a critical target for alleviating financial toxicity. Empowering patients with knowledge about treatment costs, insurance mechanisms, and available support not only facilitates informed decision-making but also enhances adherence and engagement with care plans. Educational initiatives tailored to diverse socio-economic backgrounds can bridge disparities inherent in FT distribution.

The study’s novel application of latent profile analysis contributes a refined lens through which to view financial toxicity. By moving beyond aggregate metrics to identify distinct patient subgroups, oncologists and policymakers can design stratified interventions that reflect real-world heterogeneity. Such precision in addressing FT parallels the personalized medicine trend sweeping oncology, promising improved patient outcomes and systemic cost savings.

This research also invites reflection on healthcare policy frameworks. The persistent prevalence of severe FT among lung cancer patients signals systemic inadequacies in coverage and cost management. National and regional health authorities must consider regulatory reforms that cap out-of-pocket expenses, expand insurance benefits, and incentivize value-based care models prioritizing patient financial wellbeing.

Ultimately, this investigation underscores that financial toxicity is not merely an ancillary side effect but a core determinant of treatment success and quality of life. By elucidating its complex profiles and interrelated factors, the study charts a course toward integrated care pathways that couple medical and financial support, fostering resilience in patients confronting one of the most formidable cancer types.

In conclusion, the burgeoning field of financial toxicity research is pivotal in cancer care transformation. This comprehensive profile analysis of lung cancer patients in China reveals profound economic vulnerabilities intertwined with clinical and psychosocial dimensions. As the oncology community embraces holistic patient management, financial toxicity screening and tailored interventions must become standard practice, ensuring that healing is not undermined by financial ruin.

As healthcare systems worldwide grapple with balancing innovation and affordability, insights from studies like this serve as catalysts for change. Addressing financial toxicity with the same rigor as clinical symptoms holds promise for elevating patient-centered oncology to new heights, where quality of life and survival prospects are preserved in tandem.

Subject of Research: Financial toxicity and its related factors among lung cancer patients

Article Title: Potential profile analysis of financial toxicity and its related factors among lung cancer patients

Article References: Zhang, X., Zhang, L., Geng, Z. et al. Potential profile analysis of financial toxicity and its related factors among lung cancer patients. BMC Cancer 25, 740 (2025). https://doi.org/10.1186/s12885-025-14076-1

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14076-1